Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- GAP +16.5% (also names new CEO of Old Navy), ESTC +15.7% (also authorizes new $500 mln share repurchase program), AFRM +13% (also Affirm, Shopify launch Shop Pay Installments in Australia), HAFN +1.6%, FINV +1.2%, FRO +0.8%
Other news:
- QNRX +22.8% (announces private placement financing of up to $50.0 million)
- SOLS +13.8% (ESI and SOLS mutually terminate merger agreement; SOLS also reaffirms Q3 and FY26 guidance; authorizes $500 mln share repurchase program)
- NABL +10.9% (boosts share repurchase authorization by $50 mln)
- ESI +4.1% (ESI and SOLS mutually terminate merger agreement)
- IMTX +3.1% (Perceptive Advisors bought 863,060 shares worth ~$7.5 mln)
- OTLK +2.2% (CFO to step down, names new CFO)
- SGI +2% (CEO/President disclosed the purchase of 30K shares at $62.47 - $63.06 worth approximately $1.9 mln (transaction date 8/27))
- SCHL +1.5% (enters into share repurchase agreement in private transaction)
- HTFL +1.4% (reports late breaking data from independent government-funded trial at ESC shows Heartflow FFRCT analysis reduces unnecessary invasive heart procedures by nearly half)
- MRNA +1.3% (FDA approves 2026-2027 formulas of Spikevax and mNEXSPIKE; prices upsized $2.6 bln offering of convertible senior notes; estimates that the net proceeds from the offering will be approximately $2,562.9 mln)
- NAT +1.3% (increases dividend)
- HCM +1.1% (wins China conditional approval for ATLED in FGFR2-altered intrahepatic cholangiocarcinoma)
- BTGO +1% (acquires NYDIG institutional trading business)
- SF +1% (reports July operating data)
- ALRS +1% (authorizes new 1.25 mln share repurchase program)
- LLY +1% (Mounjaro wins FDA label expansion for cardiovascular risk reduction in adults with type 2 diabetes)